AstraZeneca's antibody cocktail can prevent, treat Covid-19

11-10-2021 Mon 18:56 IST | IANS | Health

London, Oct 11:  AstraZeneca's long-acting antibody combination is both able to prevent and treat Covid-19, according to the phase three results released on Monday.

The drug, AZD7442, is a combination of two antibodies -- tixagevimab (AZD8895) and cilgavimab (AZD1061) -- which is derived from B-cells donated by convalescent patients after being infected with the SARS-CoV-2 virus, the company said in a statement.

The phase III trial conducted in 96 sites in Brazil, Czech Republic, Germany, Hungary, Italy, Japan, Mexico, Poland, Russian Federation, Spain, Ukraine, UK and US, included 903 participants who were administered a dose of 600mg of AZD7442 given by intramuscular (IM) injection.

The results showed that the cocktail reduced the risk of developing severe Covid-19 or death (from any cause) by 50 per cent compared to placebo in outpatients who had been symptomatic for seven days or less, the company said.

The drug was well tolerated in the trial.

"With continued cases of serious Covid-19 infections across the globe, there is a significant need for new therapies like AZD7442 that can be used to protect vulnerable populations from getting Covid-19 and can also help prevent progression to severe disease. These positive results show that a convenient intramuscular dose of AZD7442 could play an important role in helping combat this devastating pandemic," said Hugh Montgomery, Professor of Intensive Care Medicine at University College London, in the statement.

In the participants who received treatment within five days of symptom onset, AZD7442 reduced the risk of developing severe Covid-19 or death (from any cause) by 67 per cent compared to placebo.

AZD7442 is the first cocktail with Phase III data to demonstrate benefits in both prophylaxis and treatment of Covid-19 and is easily administered by IM injection, the company said.

"An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months," said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca.

AstraZeneca will be discussing the data with health authorities. The drug maker has also announced submission to the US Food and Drug Administration for Emergency Use Authorisation for AZD7442 for prophylaxis of Covid-19.

The results from the trial will also be submitted for publication in a peer-reviewed medical journal and presented at a forthcoming medical meeting, the company said.


More News
Russian film crew wraps shooting in space, returns to Earth
16 minutes ago
New wearable device uses sweat to monitor glucose levels
18 minutes ago
MAA president Manchu Vishnu's overenthusiastic tweet goes viral
37 minutes ago
Sasikala inaugurates AIADMK golden jubilee celebrations, calls for unity
1 hour ago
Bill, Melinda Gates walk daughter down the aisle
1 hour ago
Jaishankar arrives in Israel for 3-day visit
1 hour ago
John Cena gets into action in just his underwear in 'Peacemaker' trailer
1 hour ago
BCCI invites applications for Team India head coach's job
1 hour ago
'Bheemla Nayak' composer Thaman felicitates folk singer Mogulaiah
1 hour ago
Slip disc, sciatica can be treated with minimal invasive technique
1 hour ago
Telugu hit 'Love Story' to premiere on AHA OTT soon
2 hours ago
Qadir Ali Baig Theatre Festival in Hyderabad from October 21
2 hours ago
Win the T20 World Cup for Virat Kohli: Suresh Raina
3 hours ago
What made Delta, Delta Plus variants of Covid more virulent
3 hours ago
Decorate your home on a budget in time for the holidays
3 hours ago
Markets in euphoria, corrections are imminent
4 hours ago
Sitharaman's marathon meeting sessions with US businesses continues in NY
4 hours ago
If ISI chief is replaced Imran's govt will fall like a house of cards: Maryam Nawaz
4 hours ago
'Sarkaru Vaari Paata' poster reveals Keerthy Suresh in a sleek avatar
4 hours ago
US lawmakers protest more intensely than Indians over Amazon's rigging in India: CAIT
4 hours ago
I-T searches on groups engaged in business of Digital Marketing & Waste Management
4 hours ago
Terror vs Terror: ISIS-K using Taliban's own killing tools to step up the heat
5 hours ago
All you need to know about India's power crisis
5 hours ago
Sai Dharam Tej's recovery and his wedding news go hand-in-hand
5 hours ago
Does Chiranjeevi dislike appearing on OTT platforms?
6 hours ago
B-Town: Female stars venture into funding
7 hours ago
Spy's Eye: The pillars of nationhood
8 hours ago
'Dashrath' dies on stage, audience claps for 'great' act
8 hours ago
Protest announced against attacks on Hindu temples in Bangladesh
8 hours ago
Superstar Vijay's possible entry into TN politics keenly watched
9 hours ago